To further determine whether local FSTL1 treatment impacts AAA development, Pluronic F-127 Hydrogel containing recombinant FSTL1 was applied around the abdominal aorta after CaPO4 treatment (Fig. 7A). This evidence concerns the gene FSTL1 and triple-A syndrome.